REG - ReNeuron Group plc - Share Purchase by a Director

ReNeuronAnnouncement

13/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220713:nRSM2478Sa&default-theme=true

RNS Number : 2478S  ReNeuron Group plc  13 July 2022

ReNeuron Group plc

("ReNeuron" or "the Group")

 

Share Purchase by a Director

 

ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome
technologies, announces that Barbara Staehelin, a director of the Company, has
purchased of the Company's ordinary shares of 1p each ("Ordinary Shares").

 

 Name               Title                    Number of Ordinary Shares purchased  Resulting beneficial interest in the Company's Ordinary Shares  Percentage of Company's Total Voting Rights
 Barbara Staehelin  Senior Independent       127,000                              170,000                                                         0.30%

                    Non-Executive Director

 

 
ENDS

 

 

 

Enquiries:

 

 ReNeuron                                                  www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Chairman                                       Via Walbrook PR
 Catherine Isted, Chief Financial Officer

 Liberum Capital Limited (NOMAD and Joint Broker)          +44 (0)20 3110 2000

 Phil Walker (Investment Banking)

 Richard Lindley (Investment Banking)

 Ben Cryer (Investment Banking)

 Allenby Capital Limited (Joint Broker)                    +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                  +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                           (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings  +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About ReNeuron

 

ReNeuron is a UK based leader in proprietary stem cell derived exosome
technologies, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary exosome technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Group has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Group has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-license both of these programmes in other territories.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com)

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

 

 

  1     Details of the person discharging managerial responsibilities / person closely
        associated
 a)     Name                                                           Barbara Staehelin
 2      Reason for the notification
 a)     Position/status                                                Senior Independent Non-Executive Director
 b)     Initial notification /Amendment                                Initial notification
 3      Details of the issuer, emission allowance market participant, auction
        platform, auctioneer or auction monitor
 a)     Name                                                           ReNeuron Group plc
 b)     LEI                                                            2138003TU12CQ5TZO137
 4      Details of the transaction(s): section to be repeated for (i) each type of
        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
        place where transactions have been conducted
 a)     Description of the financial instrument, type of instrument    Ordinary Shares 1p

        Identification code                                            RENE - GB00BF5G6K95
 b)     Nature of the transaction                                      Acquisition of ordinary shares
 c)     Price(s) and volume(s)                                          Price(s)     Volume(s)

                                                              30.3169p      127,000

 d)     Aggregated information                                         £38,502.50

 e)     Date of the transaction                                        12 July 2022
 f)     Place of the transaction                                       London Stock Exchange AIM Market

d)

 

Aggregated information

£38,502.50

e)

Date of the transaction

12 July 2022

f)

Place of the transaction

London Stock Exchange AIM Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBCGDRSSBDGDD